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Neuromuscular transmission and its pharmacological blockade 
Part 3: Continuous infusion of relaxants and reversal and monitoring of 
relaxation
• Leo H .D .J. Booij
3.1.Introduction
Sometimes muscle relaxant is needed for a long peri­
od of time/ i.e. in the ICU. In other cases a constant 
depression of muscle contraction is necessary during 
anaesthesia. Such constant blockades are preferably 
reached by continuous infusion, rather then by 
administration of intermittent doses of relaxant.
Partial paralysis has always played a major role in 
the morbidity and mortality of anaesthesia. Muscle 
relaxants seem to be responsible for 50% of the 
adverse reactions during anaesthesia [1]. Residual cur­
arization contributes heavily to postoperative respira­
tory depression [2]. Anaesthetists therefore want to 
be able to reverse a neuromuscular blockade when at 
the end of anaesthesia residual paralysis exists, or 
when for other reasons a normal neuromuscular 
transmission is needed. The ability to reverse the 
effect of the muscle relaxants is one of the basic 
requirements for muscle relaxation. The effect of the 
non-depolarizers can be reversed by administration of 
anticholinesterases, then acetylcholine accumulates, 
and competes with the diminished relaxant concen­
tration for the acetylcholine receptor. The effects of 
the depolarizing relaxants cannot be reversed. 
However, suxamethonium phase II block can be 
reversed by anticholinesterases [3]. This however is 
not the case if fading in TOF occurs in patients with 
acetylcholinesterase deficiency [4].
The ability to reverse does, in my opinion, not 
mean that every single patient should receive reversal 
agents whenever non-depolarizing relaxants were 
administered during the procedure. Reversing agents 
do increase the acetylcholine concentration at all 
cholinergic receptors (nicotinic and muscarinic), and 
thus exert many side-effects, which are more pro­
nounced than the side-effects of the muscle relaxants. 
There is no reason to make the choice for a clean, rel­
atively expensive relaxant and thereafter reverse its 
effect with a dirty compound. As with all drugs, com­
pounds reversing neuromuscular blockade should 
also be administered only on indication.
Whether during anaesthesia sufficient paralysis 
does exist, or whether the patient has at the end 
recovered adequately to guarantee maintenance of a 
free airway, can be hardly evaluated by clinical signs. 
A more objective quantitative evaluation is needed 
and can be obtained by monitoring the neuromuscu­
lar transmission with electromyography, mechano- 
myography, or accelerography.
3.2. Continuous infusion of m uscle relax­
ants
Continuous infusion of muscle relaxants is indicated 
when long or constant relaxation is requested. 
Intermittent doses of relaxant will cause continuously 
changing degrees of relaxation.
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Abstract
Continuous infusion is an attractive method of 
administration when muscle relaxation is needed for a longer 
period. The pharmacokinetic behaviour of a drug is an 
important determining factor for the suitability of relaxants 
for continuous infusion. At present mainly intermediately 
long acting relaxants are used for this purpose.
At the end of surgery residual curarization may exist and 
thus anaesthesiologists prefer to be able to reverse the 
relaxants. The anticholinesterases neostigmine, 
pyridostigmine, and edrophonium are used clinically for this 
reason. Their effect is prolonged in patients with renal failure, 
and also affected during acid-base disturbances. Some other 
drugs have been used experimentally for the reversal of 
neuromuscular blockade, but are inadequate. Special 
problems can arise when reversal of a mivacurium-induced 
or antibiotic-induced blockade is wanted, or mivacurium was 
administered.
Monitoring neuromuscular transmission is an important 
feature to determine the effect of relaxant administration or 
to detect residual curarization. It is based on stimulation of 
peripheral nerves with either single twitch, train of four, 
tetanic or double burst stimulation. The evoked response can 
be quantitated with mechanomyography, 
electromyography, or accelerography. The response of the 
various muscles to nerve stimulation varies due to the 
different characteristics of the muscles. Clinically, the use of 
the adductor polHcis muscle is advised.
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When muscle relaxants are intermittently adminis­
tered a continuously changing degree of neuromus­
cular blockade is present, depending on the change 
in relaxant plasma concentration.
Administration of relaxant by continuous infusion 
leads to a constant concentration, and thus a stable 
effect. This, however, demands high controlability of 
the drug, and thus pharmacodynamicaliy a rapid 
onset, a short duration, and a rapid recovery. This can 
pharmacokinetically be translated in short elimination 
half-life and large plasma clearance. A large plasma 
clearance is reached by rapid redistribution, rapid 
metabolism, or rapid excretion. This would mean that 
suxamethonium, mivacurium, atracurium, vecuro­
nium, and rocuronium are suitable for continuous 
infusion. Relaxants with a long duration of action are 
likely to accumulate, and thus will lead to prolonged 
duration of action when administered by infusion. 
The amount of relaxant that must be infused depends 
on the patients' weight and length, the pharmacoki­
netic characteristics of the relaxant, the presence of 
concurrent diseases, and the simultaneous use of 
other drugs. If the rate of drug delivery is equal to its 
plasma clearance, a steady state concentration can be 
reached. Such an infusion rate equals the desired 
plasma concentration times the clearance. It will, 
however, take an infusion during five to seven times 
the elimination half-life before the steady state is 
reached. This can be shortened by administration of a 
loading bolus dose followed immediately by the con­
tinuous infusion. Because of the high interindividual 
variability in effect of the relaxant it is advisable to 
monitor the neuromuscular function.
Computer controlled closed loop systems have 
been used for continuous administration of muscle 
relaxants [5 6], With such systems a preset degree of 
neuromuscular blockade can be maintained. The nec­
essary device incudes a monitor, a comparator, and 
an infusion pump. The rate of infusion is determined 
by measurement of the degree of blockade. This indi­
cates that some overshoot, and undershoot, will be 
present, depending on the time constant of the par­
ticular relaxant administered. The shorter the time 
constant, i.e. the more rapid onset, and shorter dura­
tion, the better the performance of the closed loop 
system can be, and the smaller the over-, and under­
shoot. Versatile systems for closed-loop administra­
tion of atracurium and vecuronium have been devel­
oped [7]. Rocuronium has also been administered by 
continuous infusion in a closed-loop feedback control 
system [8]. Such closed-loop systems are operated 
either:
1. proportional, in which the controller gain is uni­
formly proportional to the input (change in infu­
sion speed)
2. integral, in which the controller acts with increas­
ing response to an error signal
3. derivative, in which the controller anticipates on 
the trend of the error signal, and thus applies a cor­
recting action ahead of this error (on-off control).
Others have developed systems that hold pharmaco­
kinetic algorythms to reach a desired plasma concen­
tration [9]. In these systems there is most of the time 
no feed-back from the degree of neuromuscular 
blockade, and thus accumulation and prolonged 
effect may occur in individual cases.
Infusion is also possible without a closes loop
system. After a bolus dose of the relaxant a continu­
ous infusion is started at a particular rate. When the 
drugs are administered in the intensive care unit a 
lower dose is usually sufficient to reach adequate 
muscle relaxation.
3.2.1. Infusion of suxamethonium
After endotracheal intubation on suxamethonium it is 
possible to maintain the neuromuscular blockade 
with a continuous infusion of suxamethonium. A rate 
of 70-80 pg/kg is usually adequate in adults. 
However, large variability in the required infusion 
rates exists [10]. A disadvantage of this method is that 
tachyphylaxis and phase II block (non-depolarizing 
characteristics) will soon develop. Phase II block has 
an unpredictable duration, but can be reversed with 
anticholinesterases [11].
3.2.2. Infusion rates for non-depolarizing relaxants
Atracurium is suitable for continuous infusion at a rate 
of 7-8 pg/kg/min. Cisatracurium (BW 51W89) can be 
used by continuous infusion; an infusion rate of 1.4 
pg/kg/min is appropriate to maintain a 95% neuro­
muscular blockade. An appropriate rate of infusion for 
mivacurium is 5-10 pg/kg/min. The infusion rate 
must be decreased after ca. 30 min to prevent cumu­
lation [12].
Pancuronium, although long lasting, has been used 
for continuous infusion at a rate of 0.06-0.1 mg/kg/h. 
Vecuronium is suitable for continuous infusion at a 
rate of 1-2 pg/kg/min. In intensive care the infusion 
rate for paediatric patients is 0.9 pg/kg/min for neo­
nates, and 1.6 pg/kg/min for older children [13]. 
With rocuronium, under nitrous-opioid anaesthesia, 
10 pg/kg/min is needed, under enflurane anaesthesia 
7 pg/kg/min, and under isoflurane anaesthesia 6 
pg/kg/min [14]. The recovery, after stopping the infu­
sion during isoflurane anaesthesia, is slower when 
compared to enflurane, which, in turn, is slower com­
pared to balanced anaesthesia. The pharmacokinetic 
parameters for rocuronium upon infusion are similar 
to the parameters after bolus administration [15].
3.3,Reversal of neuromuscular blockade
Because non-depolarizing muscle relaxants are effec­
tive through competition with acetylcholine for the 
binding places at the nicotinic postjunctional recep­
tor, it is possible to reverse their effects by increasing 
the amount of acetylcholine available in the biophase. 
This can be obtained by decreasing the break down 
of acetylcholine through inhibition of acetylcholines­
terase; another possibility is the increase in acetylchol­
ine release.
3.3.1. indications for reversal
Reversal of neuromuscular blockade is needed when 
rest curarization exists. There is no difference in the 
incidence of residual curarization between the differ­
ent types (depolarizing or non-depolarizing, benzyliso- 
quinoline or steroid) of relaxant. However, shorter 
acting relaxants are less likely to cause residual curar­
ization than longer acting ones [16]. Especially on 
repeated administration do the long-acting ones tend 
to cumulate. Another indication for reversal exists 
when it is impossible to artificially ventilate the 
patient after administration of relaxant. In the past it
has clearly been demonstrated that it ¡s impossible to 
reverse deep blockades. Such deep block exists 
immediately after administration of relaxant during 
induction of anaesthesia. Reversal should only be 
attempted if there is some return of response to nerve 
peripheral stimulation, i.e. 1-15% of the response to 
single twitch stimulation [17 18]. The more spontane­
ous the recovery is present, the faster the reversal will 
be.
3.3.2. Drugs used for reversal 
33.2,1. Anticholinesterases
Acetylcholinesterase plays an important role in neuro­
muscular transmission by eliminating the acetylcho­
line molecules from the cleft through hydrolytic trans­
formation. Only 50% of the acetylcholine molecules 
liberated from the nerve terminal reach the postsyn- 
aptic receptors, the rest is hydrolysed previously. The 
effect of acetylcholinesterase can be inhibited by 
binding of drugs to the enzyme. In the reversal of 
neuromuscular blockade the anticholinesterases neo­
stigmine, pyridostigmine and edrophonium are used; 
physostigmine is used in the treatment of central anti­
cholinergic syndrome (Fig. 3.1). Neostigmine and 
pyridostigmine are themselves hydrolysed by acetyl­
cholinesterase (acid transferring anticholinesterases 
binding to both the anionic and esteratic sites) 
whereas edrophonium is not (prosthetic anticholines­
terase binding to the anionic site) [19]. However, this 
last compound rapidly dissociates from the enzyme, 
but can recombine immediately.
The effect of the anticholinesterases is not only 
restricted to inhibition of cholinesterase, but also 
includes prejunctional acetylcholine releasing effects 
and some direct effects on the postjunctional recep­
tor [20]. In large concentrations they may occlude 
acetylcholine-operated ion-channels [21], With neo­
stigmine these additional effects are stronger than 
with pyridostigmine or edrophonium [22]. 
Edrophonium has a more pronounced prejunctional 
effect than neostigmine and pyridostigmine [23 24]. 
The dose of anticholinesterase required to reverse a 
block is dependent on the degree of neuromuscular 
blockade existing, on the type of relaxant adminis­
tered, on the type of anaesthetic/ and on the type of
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anticholinesterase used [25-29]. The quarternary anti­
cholinesterases neostigmine, pyridostigmine or edro­
phonium have minimal passage through the blood- 
brain barrier and thus, contrary to physostigmine, 
have no significant central nervous system effects. 
They are water soluble and thus are they excreted 
mainly via the kidneys.
With the current relaxants it is impossible to reverse 
a deep neuromuscular blockade (high relaxant con­
centration in the biophase). Therefore the rate of 
spontaneous recovery should be considered when 
reversing a blockade [30], However, the shorter act­
ing the muscle relaxant, the easier it is to reverse a 
blockade. In clinical practice it is difficult to take all 
these factors into consideration. Therefore an initial 
dose of the reversal agent should be administered 
whereafter the recovery should be measured, and if 
needed a supplemental dose of the agent adminis­
tered. In general a dose of 60 M9/kg neostigmine 
seems to be adequate [31 32], For edrophonium the 
dose is 1000 (jg/kg [33]. The dose for pyridostigmine 
is 300 jjg/kg. In elderly patients the duration of effect 
of neostigmine and pyridostigmine is significantly 
increased, similar to the effect of most non-depolariz­
ing relaxants [34]. This is correlated with a different 
pharmacokinetic behaviour in the elderly [35]. 
However, the effect of edrophonium is not prolonged 
[36]. There is no difference in the dose requirement 
for edrophonium between infants, children and 
adults. With neostigmine, infants need less than 
adults. The effect of neostigmine and pyridostigmine 
is potentiated by 4-aminopyridine [37]. This last com­
pound is also able to reverse antibiotics-induced neu­
romuscular blockade [38]. It has been demonstrated 
that too small a dose of neostigmine leads to residual 
relaxation [39] and that too large dose leads to neo­
stigmine-induced neuromuscular blockade [40], 
Antagonist thus should be titrated under close moni­
toring of the neuromuscular function.
Renal failure prolongs the effect of most non-depo­
larizing muscle relaxants, which may cause a higher 
incidence of residual curarization in those patients 
[41]. However, it has been demonstrated that in 
patients with renal failure the plasma clearance of 
neostigmine is decreased and the elimination half-life 
prolonged because neostigmine is excreted for 50% 
unchanged via the kidneys [42]. In renal failure the 
plasma clearance is decreased, thus recurarization is 
unlikely to occur. Also with pyridostigmine and edro­
phonium, the clearance is decreased in renal failure 
patients [43 44]. Pyridostigmine is excreted for 80% 
unchanged in the urine and is for the rest mainly 
metabolized into 3-hydroxy-N-methyl-pyridinium 
which is rapidly glucuronidated. Neostigmine is 
excreted unchanged for 50% in the urine and further 
metabolized mainly into 3-hydroxy-phenyl-trimethyl- 
ammonium. The renal excretion occurs by glomerular 
filtration and tubular excretion.
Hepatic diseases have no significant effects on the 
pharmacodynamics and pharmacokinetics of anti- 
CHj cholinesterases. However, the pharmacodynamics of 
many relaxants is impaired in such patients (see sec­
tion 2.5.2), and thus reversal appears to be more diffi­
cult. When neostigmine is administered in patients 
Figure 2.6 with cirrhosis or neoplastic liver disease, a prolonged
depression of plasma cholinesterase activity is 
present. This would indicate a prolonged effect of
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neostigmine in such patients [45]. Such an effect is 
because it is affected by plasma cholinesterase, likely 
to occur also with pyridostigmine, but not with edro­
phonium.
Disturbances in acid-base balance not only inter­
fere with the muscle relaxants (monoquarternary 
relaxants are potentiated, bisquarternary relaxants are 
not significantly changed by acidosis [46]), but also 
with the anticholinesterases. Respiratory acidosis and 
metabolic alkalosis decrease the blockade-reversing 
effect of the anticholinesterases. From animal studies 
it can be concluded that in hypokalemia more neo­
stigmine is needed to reverse a pancuronium-induced 
neuromuscular blockade. It is likely that these results 
apply also to other non-depolarizing relaxants. 
Recently it has been demonstrated that neostigmine- 
induced reversal of neuromuscular blockade is not 
affected by C 0 2-induced acid-base changes [47].
From animal studies can it be concluded that in hypo­
kalemia more neostigmine is needed to reverse a pan­
curonium-induced neuromuscular blockade [48], It is 
again likely that these results apply also to other non­
depolarizing relaxants. Respiratory acidosis and meta­
bolic alkalosis prevent the antagonistic effect of neo­
stigmine in cats [49 50]. However, in other studies has 
It been demonstrated that antagonism with neostig­
mine is not affected by respiratory acidosis or alkalo­
sis.
It was demonstrated that the recovery rate after 
neostigmine administration was not different during 
hypothermia or normothermia; however, due to the 
small number of patients, further study is needed.
The pharmacokinetic behaviour of all three anti­
cholinesterases is similar. After a peak plasma concen­
tration is reached immediately after intravenous 
administration, there is a rapid decline in concentra­
tion during 5-10 min, corresponding to the redistri­
bution phase. Thereafter a slower decrease in plasma 
concentration is seen during the elimination phase. 
The volume of distribution ranges from 0.7-1 A  l/kg 
and the elimination half-lives rate 60-120 min and the 
clearances 8-16 ml/kg/min [51]. As mentioned earlier 
neostigmine is mainly eliminated through the kidney, 
whereas pyridostigmine is largely metabolized in the 
liver, but also extensively excreted through the kid­
neys.
Anticholinesterases cause an increase of acetylchol­
ine at all receptor places (nicotinic and muscarinic). 
This results in side-effects with signs as bradycardia, 
excessive secretions from salivary and bronchial 
glands, and increased bronchial and intestinal 
smooth muscle tone. The adverse effects are dose 
dependent, and are most pronounced with neostig­
mine and least pronounced with edrophonium [52]. 
The drugs, except edrophonium, also inhibit plasma 
cholinesterase activity, thus they prolong the effect of 
suxamethonium [53 54]. The decrease in plasma 
cholinesterase activity lasts for 30-60 min. Atropine, 
but especially glycopyrrolate, prevents many of the 
cardiovascular effects of the anticholinesterases, but it 
is not able to prevent the intestinal effects [55 56]. 
Anticholinesterases can also cause bronchoconstric- 
tion.
The anticholinesterases have strong muscarinic 
effects on the gastro-intestinal tract. At least for neo­
stigmine it has, in one study, been demonstrated that 
it increases the incidence of nausea and vomiting in
the immediate postoperative period [57]. Other 
workers have also found this effect [58]. In the same 
study it was indicated that suxamethonium seems to 
be related to a higher incidence of nausea and vomit­
ing than non-depolarizers. However, other investiga­
tors found a decrease in the incidence of nausea and 
vomiting after reversal of neuromuscular blockade 
[59]. This was confirmed later for neostigmine [60].
Administration of anticholinesterases carries the risk 
of induction of a central cholinergic syndrome. It is 
characterized by delayed recovery, restlessness and 
agitation, frequently hypertension, tachycardia 
mydriasis and urinary retention are seen. At repeated 
dosages of anticholinesterase, neuromuscular block 
may occur from transient depolarization of the recep­
tors and blockade of open confirmation channels 
[61].
Some anticholinesterases are not routinely used for 
the reversal of a neuromuscular blockade. Tacrine 
(tetrahydroaminoacridine, or 1,2,3,4-tetrahydro-9- 
acridinamine) is an anticholinesterase that has in the 
past been used to extend the effect of suxametho­
nium. Because of its stimulant effect on the central 
nervous system, it has also been used to lessen mor- 
phine-induced respiratory depression. Its inhibition of 
benzodiazepine receptor binding is unlikely to be of 
clinical value [62], Also velnacrine, a tacrine deriva­
tive, has a neuromuscular transmission-stimulating 
effect. Galanthamine is a vegetable tertiary alkaloid 
isolated from snowdrop bulbs. It inhibits acetylcholi­
nesterase [63]. It also inhibits plasma cholinesterase, it 
is said to have fewer muscarinic effects than the other 
anticholinesterases, and it crosses the blood-brain 
barrier. Also, some of its derivatives have anticholiner­
gic effects [64]. Galanthamine is widely used in 
Eastern European countries for the reversal of neuro­
muscular blockade. Western studies, however, dem­
onstrated a slower effect than after neostigmine in 
reversal of pancuronium, alcuronium, gallamine, and 
tubocurarine [65 66], Salivation, nausea, blurred 
vision, and bradycardia are known side-effects [67]. 
Galanthamine seems to have some analeptic effect 
and reverses respiratory depression from opiates, but 
it has also been claimed that galanthamine has anal­
gesic effects too. Further research is needed to unrav­
el these observations. These and other central ner­
vous system and peripheral effects of galanthamine 
have been reviewed recently [68]. Galanthamine is 
cleared for 25-30% by the kidneys and follows first 
order kinetics. It is metabolized into the inactive 
metabolites epigalanthamine and galanthaminone, 
which are excreted in the urine. The plasma clearance 
is 0.24 l/kg/h, the terminal half-life is 5.68 h [69]. 
Others found a Tl/kt of ca. 6.5 min, a T,^ of 265 min 
with a plasma clearance of 0.32 l/kg/h, a renal clear­
ance of 81.6 ml/kg/h, and minimal biliary excretion.
3.3.2.2. Aminopyridines
4-Aminopyridine and its analogues increase presyn- 
aptic acetylcholine release through dose dependent 
promotion of cellular calcium influx and potassium 
efflux [70], This increases the competition with non­
depolarizing relaxants for the postjunctional acetyl­
choline receptors. Also, aminopyridines increase the 
muscle contractility through increased calcium 
release from the sarcoplasmatic reticulum [71]. 
Therefore they potentially may be drugs that can be
used for reversal of neuromuscular block.
4-Aminopyridine is a tertiary amine that passes the 
blood-brain barrier, causing central nervous system 
effects. In clinical studies, 4-aminopyridine had a rela­
tively weak effect, and can, in the dosages used, only 
partly reverse the non-depolarizing blockade [72]. It, 
however, was able to reverse an antibiotic induced 
block [73]. Furthermore it potentiates the effect of the 
anticholinesterases [74]. Because of a cental analeptic 
effect, 4-aminopyridine has been used for the reversal 
of opioid induced respiratory depression and the 
antagonism of ketamine-diazepam anaesthesia [75 
76]. The larger percentage of 4-aminopyridine is 
excreted unchanged in the urine, thus a prolonged 
effect in patients with renal failure must be expected.
2,4- and 3,4-Diaminopyridine are more potent and 
more polar compounds and thus cross the blood- 
brain barrier to a lesser extent than 4-aminopyridine. 
They have more specific peripheral effects [77]. These 
compounds and some of their analogues are current­
ly being investigated.
Acetamino-pyridine-N-oxide is another more polar 
derivative, which is also more potent than 4-amino- 
pyridine [78].
Aminopyridines have been used in a number of 
neurological disorders. Amongst them are Lambert- 
Eaton syndrome (muscle weakness, hyporeflexia, 
autonomic dysfunction), myasthenia gravis, tempera­
ture sensitive multiple sclerosis, and botulism [79-82]. 
When administered in patients with Alzheimer's dis­
ease, improvement in cognitive function was 
observed [83]. Recently 4-aminopyridine was used to 
improve nerve conduction in patients with spinal 
cord injury [84].
3.3.2.3. Genuine mono acetate
Germine mono-acetate is able to antagonize both 
depolarizing and non-depolarizing neuromuscular 
blockade. The mechanism seems to be a direct effect 
on the muscle fibre [85]. Although its efficacy has 
been demonstrated in animal studies, the compound, 
to my knowledge, has not been routinely used in the 
clinic [86 87]. In cats the compound was able to 
reverse muscle relaxation from dantrolene [88].
3.3.3. Reversal of mivacurium
Mivacurium is rapidly hydrolysed by plasma cholines­
terase, which is inhibited by the acetylcholinesterase 
inhibitors [89]. Hence, theoretically the anticholines­
terases might delay the metabolism of mivacurium. It 
has been demonstrated that neostigmine readily 
reverses mivacurium, once some spontaneous recov­
ery is present [90 91]. When, however, deeper block­
ade is present the recovery is, compared to spontane­
ous recovery, delayed by administration of neostig­
mine [92]. This was confirmed in experimental situa­
tions in humans, where administration of edropho­
nium or neostigmine during ongoing constant infu­
sion of mivacurium resulted in an increase in the plas­
ma concentration of the relaxants [93 94]. This indi­
cates a decrease in the metabolism of mivacurium, 
induced by anticholinesterase administration. 
However, edrophonium does not inhibit plasma chol­
inesterase, and therefore this result is conflicting. In a 
clinical study was it found that indeed edrophonium 
does not prolong the effect of mivacurium [95]. This 
would indicate that edrophonium, but not neostig­
mine, is the reversal agent of first choice in a mivacu- 
rium-induced neuromuscular block.
3.3.4. Reversal of antibiotics-induced neuromuscu­
lar blockade
Antibiotics of the aminoglycoside, lincosamide, poly­
peptide, and tetracycline series are other examples of 
drugs showing interaction with muscle relaxation. 
These compounds can cause curarization when 
administered up to 4-6 h after complete recovery of 
the neuromuscular blockade, even when antagonized 
with neostigmine or pyridostigmine (Booij, unpub­
lished data). The polypeptides have a local anaesthet­
ic effect in that they block acetylcholine receptor ion- 
channels [96]. This effect is not reversed by anticholi­
nesterases and only partly by 4-aminopyridine [97]. 
Aminoglycosides decrease acetylcholine release and 
lower the postjunctional sensitivity for acetylcholine 
[98]. Again neostigmine has little reversing effect on 
such a blockade. Tetracyclines interfere with calcium, 
which is involved in acetylcholine release [99]. 
Neostigmine has no effect Lincomycin and clindamy­
cin block the ion channels and depress muscle con­
tractility [100], Both neostigmine and 4-aminopyri- 
dine are partially effective in antagonizing the block­
ade [101].
3.3.5. Use of reversing agents in patients with neu­
romuscular diseases
In general there is, in patients suffering from neuro­
muscular diseases, a higher sensitivity to muscle relax­
ants than in normal patients. Also the reversal agents 
may have a different effect from normal patients. In 
myotonic patients reversal with neostigmine, or the 
use of a nerve stimulator, can result in sustained mus­
cle contraction [102-104], In patients with hemiple­
gia the afflicted side is more sensitive to the reversal of 
a non-depolarizing blockade with anticholinesterases 
than is the non-afflicted side [105]. When patients 
with myasthenia gravis receive anticholinesterase 
treatment, a decrease in plasmacholinesterase may 
occur. Increased sensitivity to suxamethonium can 
then be expected [106]. Myasthenic patients are 
more sensitive to non-depolarizers than normal 
patients. When in myasthenic patients acetylcholines­
terase inhibitors are administered to reverse a non­
depolarizing blockade, a depolarizing blockade from 
the cumulated acetylcholine may occur [107]. Thus 
reversal of blockade should be done very carefully, 
and only if absolutely indicated.
3.4.M onitoring neurom uscular transm is­
sion
That it is difficult to evaluate neuromuscular function 
without use of a monitor has been repeatedly demon­
strated, In one study in 72 patients, it was found that, 
although neostigmine was administered routinely 
and that the neuromuscular function was considered 
completely safe, in 30 patients (42%) a train-of-four 
response of less than 0.70 existed. Of these patients 
24% could not sustain a head lift for 5 s [108]. Similar 
results were found by other investigators [109 110]. 
In another study it was found that 55% of the Post 
Anaesthetic Care Unit patients had mild hypoxia and 
13% had severe hypoxia [111]. In 55% of the patients 
this was the case although they received supplemen-
tai oxygen. The hypoxia was not recognized by the 
staff in 95% of the cases, and was already existing on 
arrival in the PACU in 32%. Residual paralysis not only 
carries the risk of respiratory depression, but also 
decreases the ability to cough or sigh and to transport 
mucus. Thus development of atelectasis is more likely 
to occur. It has been proven that residual curarization 
does occur more frequently with the long-acting than 
with the intermediate and short-acting relaxants [112 
113], In one study the incidence of residual curariza­
tion after pancuronium was 45% and after vecuro­
nium 8% [114]. Many more examples can be found 
in the literature, proving that monitoring of neuro­
muscular transmission is demanded for the sake of 
the patient's safety [115]. Other reasons for monitor­
ing are the wide interindividual variability in the 
response to relaxants, and the possibility of drug 
interactions [116 117].
3.4.1. Methods of evaluating neuromuscular trans­
mission
Clinical evaluation of neuromuscular function is done 
by determining the patient's ability to lift the head, to 
stretch an elevated arm, or to protude the tongue for
5 s. Determination of grip strength is also used [118 
119]. All these tests have proven to give an indication 
of muscle function, but also to be unreliable to abso­
lutely guarantee the patient's safety [120 121]. Also 
they require the cooperation of the patient, which, 
during or immediately after anaesthesia, frequently is 
not available. Visual or tactile evaluation of the 
response to peripheral nerve stimulation is considered 
better, but also is not sufficiently safe [122]. 
Quantitative monitoring is the most reliable one. It 
can be done with electromyography (EMG), mecha- 
nomyography (MMG) and accelerography. There is a 
difference in the response obtained by the methods 
of quantitation of the response [123 124]. With non- 
depolarizers the MMG is more depressed than the 
EMG; with suxamethonium the opposite is seen [125 
126]. MMG is critically dependent on maintenance of 
a constant preload. Thus fixation of arm and thumb 
are requested. This is not necessary with the use of 
accelerography. With accelerography there is, in com­
parison to MMG, an underestimation during onset of 
block and an overestimation during recovery [127]. 
Both EMG and MMG are influenced by temperature 
[128]. With accelerography it is possible to prevent 
postoperative rest curarization, even when long-act­
ing relaxants are used [129]. This of course is also pos­
sible with mechanomyography and electromyogra- 
phy; however, these methods are impractical during 
routine anaesthesia.
3.4.2. Methods of nerve stimulation
For nerve stimulation single twitch (T,, 0.1-0.15 Hz; 
duration, 0.1 ms), train-of-four (TOF, 2Hz; duration, 
0,1 ms, interval 10-12 s), tetanus (Tet, 50 Hz; dura­
tion, 5 s), and double burst (DBS, two bursts of three 
stimuli at 50 Hz, interval 0.75 s) stimulation are used 
[130 131]. After tetanus a post-tetanic potentiation 
(PTP) and post-tetanic count (PTC) can be per­
formed. All stimuli should be administered at a supra­
maximal and constant current (usually 50-65 mA) 
[132].
3.4.2.1. Single twitch stimulation
The response to single twitch stimulation decreases 
when 70% of the acetylcholine receptors are occu­
pied with non-depolarizing relaxant; at 90% receptor 
occupation full blockade exists. This means that 70% 
of the receptors are still occupied when the response 
to twitch stimulation has fully recovered. With 
increase in stimulation frequency the number of 
receptors that is still occupied decreases when the 
response shows complete recovery. At 75% depres­
sion of the response good surgical relaxation starts to 
exist.
3.4.2.2. Train-of-four stimulation
When the stimulation frequency is above 1.5 Herz, 
fading in response will be observed upon administra­
tion of repeated stimuli in the presence of non-depo­
larizing muscle relaxants. This is the result of a 
decrease in acetylcholine release. Fade after tetanic or 
train-of-four stimulation is essentially a prejunctional 
effect; suppression of the single twitch response is pri­
marily a postjunctional effect [133]. Maximum fading 
is, at 2 Hz, reached at the fourth stimulus. Post-stimu- 
lation potentiation, as after tetanus, is not seen in that 
situation. For this reason the 2 Hz frequency was cho­
sen for the train-of-four stimulation. The interval 
between the individual trains-of-four is important. 
The shorter the interval is, the higher the degree of 
blockade, and the faster the onset [134]. Thus in 
order to compare data from various studies the same 
stimulation rate at intervals of 0.1-0.12 s should be 
used. The ratio of the height of the first and the fourth 
response is called the train-of-four ratio. For the train- 
of-four ratio a baseline control value is needed. There 
exists a relaxant independent relationship between 
the train-of-four ratio and the degree of depression of 
muscle concentration upon single twitch stimulation 
135]. This is best seen when one or more of the four 
responses is disappearing, i.e. in the train-of-four 
count Disappearance of the fourth, third and second 
response to train-of-four stimulation relates to, 
respectively, 60-70, 70-80, and 80-90% decrease in 
response to single twitch stimulation.
The TOF is believed to be the clinically most suit­
able method for evaluation of neuromuscular block­
ade [136]. It is generally accepted that when the 
response to train-of-four stimulation is 0.75 or higher, 
an adequate recovery of neuromuscular blockade 
exists [137]. The safest situation exists if the responses 
to stimulation are quantitated electromechanically, 
electromyographically, or accelerographically,
3.4.2.3. Double burst stimulation
With double burst stimulation two bursts of three 
stimuli at a frequency of 50 Hz are administered with 
a 0.75 s interval. They result in two short duration 
contractions, which are equal in strength in non-para- 
lysed patients [138]. In the presence of non-depolar­
izing relaxants the second response is weaker than 
the first This is a more reliable measure than train-of- 
four responses [139]. It is more painful than train-of- 
four stimulation, and thus cannot be recommended 
during the recovery room period. The interval 
between two double burst stimuli should be at least 
12 s.
3.4.2 A. Tetanic stimulation, post-tetanic potentiation 
and post-tetanic count
When during 5 s a train of supramaximal stimuli at a 
frequency of 50 Hz is administered, the individual 
responses will confluence into one sustained muscle 
contraction that iasts as long as the stimulus is 
applied.
Already at stimulation frequencies above 5 Hz, such 
a fusion of the individual responses, i.e. tetanization, 
is seen. When non-depolarizing muscle relaxants are 
administered the peak tetanic contraction is not 
maintained and fading occurs. Stimulation frequen­
cies above 50 Hz also may result in spontaneous fade 
in response (fatigue), even in the absence of muscle 
relaxants [140].
If immediately after 5 s duration tetanic stimula­
tion, a 1 Hz single twitch stimulation is applied, a 
potentiation (facilitation) in the response will be seen 
for 90-120 s (post-tetanic potentiation). This is the 
result of increased mobilization and release of acetyl­
choline (see Chapter 1). The deeper the degree of 
blockade the less likely it is that such post-tetanic 
responses are seen, and thus their appearance is an 
indication for recovery of blockade [141], Such recov­
ery is correlated to the number of potentiated single 
twitch responses observed after tetanic stimulation 
(post-tetanic count). Other characteristics of post- 
tetanic potentiation are a decrease in the fade in 
response to train-of-four and double burst stimula­
tion, and a decrease in the latency period between 
the beginning of a muscle action potential and the 
rise in muscle tension. The mechanism of post-tetanic 
potentiation and post-tetanic count is an increase in 
acetylcholine release, with liberation of post-synaptic 
receptors from relaxant, and increased muscle con­
tractility.
Post-tetanic count should not be applied more 
than once every 5-6 min because tetanic stimulation 
will speed up recovery of blockade in the stimulated 
muscles [142 143]. Post-tetanic facilitation is a pre- 
synaptic phenomenon, and hence depends on the 
relaxant administered.
3.4.3. Differences in response between various 
muscles
Differences in sensitivity of muscles exists for the 
relaxants. This is important because the safety of the 
patients depends on the function of respiratory and 
hypopharyngeo-laryngeal muscles.
In the evaluation of a neuromuscular blockade 
stimulation of the ulnar or median nerve near the 
wrist is especially appropriate. Not only are these 
nerves most of the time easily accessible for stimula­
tion, but also a good correlation exists between the 
response of the muscles innervated by them, and the 
ability of the patient to breath spontaneously. There 
exist only minor, clinically irrelevant differences in the 
sensitivity of the various hand muscles, if measured 
with one and the same method. However, there are 
major differences between the muscles in the hand 
and those in other body areas [144]. Since anaesthe- 
siologists most of the time also have easy access to 
the head of the patients, stimulation and evaluation 
of the response in facial muscles have been clinically 
used. However, these muscles are much more resist­
ant to relaxants than the adductor poliicis, and thus
underestimation of relaxation of the respiratory mus­
cles is likely to occur [145]. It accordingly has been 
proven that these muscles have completely recovered 
earlier than the adductor poliicis or the respiratory 
muscles. This leads to underestimation of the neuro­
muscular blockade [61],
For a long time has it been recognized that a respir­
atory sparing effect of non-depolarizers exist [146]. 
Respiration still is unaffected when the muscles in the 
hand are completely paralysed [147]. The potency of 
pancuronium on the diaphragm is half that on the 
adductor poliicis muscle [148]. Intercostal, and 
abdominal muscles have a greater sensitivity to pan­
curonium than the diaphragm [149]. The onset of 
action of relaxants is faster in the diaphragm than in 
the adductor poliicis muscle [150], These facts may 
explain the good correlation between surgical relaxa­
tion as judged by the surgeon, and the relaxation of 
the adductor poliicis muscle. It also can be concluded 
that monitoring the adductor poliicis muscle is a valu­
able method to guarantee either sufficient surgical 
muscle paralysis or adequate recovefy of the respira­
tory muscles.
The adductor muscles of the larynx are, like the 
diaphragm, resistant to relaxants, and show a faster 
onset and recovery [151]. Recently a model was 
described showing that the faster onset is due to an 
earlier peak concentration of the relaxant in the res­
piratory muscles, likely because of greater perfusion 
[152]. This explains why adequate intubation condi­
tions exist when blockade in the adductor poliicis 
muscle is only 8 0 -90% .
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